Research Corporation Technologies, Inc. (RCT), of Tucson, has partnered with Isogenica, of Cambridge, U.K., to access Isogenica’s CIS display platform for the screening of proprietary libraries of a new antigen-binding protein scaffold.

The RCT libraries are part of a biologics discovery platform to identify engineered antibody fragments called ABDURINS™ for development into therapeutic agents.  ABDURINS™ retain the desired long half-life of an antibody’s CH2 domain and are engineered for enhanced stability, epitope binding and other properties. To facilitate screening of the novel ABDURIN™ libraries, RCT has partnered with Isogenica to provide interested parties access to their proprietary, high throughput display and screening platform called CIS display. CIS display can screen significantly larger libraries and isolate and optimize lead binders in a fraction of the time it takes using phage display.  In addition to CIS display, Isogenica will support RCT through deep sequencing and related bioinformatics tools that can inform the optimisation of the selected ABDURINS™.

“Isogenica’s CIS display offers a significant advantage over other screening systems by allowing for primary screening and binder optimization in one system.  The pairing of CIS display with our ABDURIN™ platform will be an attractive offering to potential partners,” stated Dr. Kurt Gehlsen, Vice President and CSO of RCT.

Dr. Kevin Matthews, CEO of Isogenica commented, “Our agreement with RCT underlines the value that CIS display brings to companies that are pioneering new antibody scaffolds for the development of better medicines.  We look forward to supporting the deployment of RCT’s ABDURIN™ library and working with their biopharma collaborators to find new therapeutic candidates.”

Notes to Editors

About Isogenica

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display.  Founded in 2000, Isogenica has developed a unique capability in the field of protein engineering.  Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.

For further information contact:

Kevin Matthews
CEO, Isogenica
Tel: +44 (0)1799 533682
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

About Research Corporation Technologies (RCT)

RCT is a Tucson, Arizona-based technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT’s ABDURIN ™ platform has been developed under collaboration with Dr. Dimitri Dimitrov’s Protein Interactions Group of the National Cancer Institute at the National Institutes of Health. To learn more, see

For RCT communications contact:
Rebecca Buescher
Tel:  1-520-748-4411
E: This email address is being protected from spambots. You need JavaScript enabled to view it.


Antibodies in Drug Discovery 2016

Cambridge, UK | 9th-10th February 2016
Isogenica is pleased to be attending this event and looks forward to meeting you

Read More

9th Annual Proteins & Antibodies Congress 2016

London, UK | 18th-19th April 2016
Isogenica is pleased to be attending this event and looks forward to meeting you

Read More


Abdurin Therapeutic Scaffold

Cambridge, UK | 27th August 2015.


Isogenica and Research Corporation Technologies (RCT) publish paper exemplifying RCT’s proprietary Abdurin therapeutic scaffold...

Read More

Isogenica Secure Funding

Cambridge, UK | 14th July 2015

Today, Isogenica, Cambridge UK and Imperial College London secure funding from the...

Read More